Dr. Andrew Fleischman is the founding CEO of CLEU Diagnostics, and is responsible for the vision and operations of the company. Dr. Fleischman is an accomplished physician-scientist and life sciences entrepreneur, having founded three successful companies since 2018 which have received over $16 million in funding from National Institute of Health. Dr. Fleischman received a M.D. from Thomas Jefferson University in 2015 and completed residency training in anesthesiology at Thomas Jefferson University Hospital. The inspiration for LabSimple comes from Dr. Fleischman's own hands-on experience working at various health systems in the Philadelphia area. In addition to leading the team in the development of the LabSimple platform, Dr. Fleischman is actively involved in drug discovery and clinical stage drug development. In 2021, Dr. Fleischman led a team of medicinal chemists to discover a breakthrough drug for sickle cell disease, which is now entering human clinical trials. As an experienced founder and company builder, Dr. Fleischman has broad experience in basic and clinical sciences, intellectual property, regulatory strategy and business development.

Tim Ladin has served as Chairman of the Board of CLEU Diagnostics since 2023. Mr. Ladin served for almost two decades as Vice President, General Counsel, and Chief Compliance Officer of MFP Investors LLC, MFP Partners, L.P., MFP Ventures, LLC, the Price Family Foundation, and related entities of the family office of Michael F. Price. Mr. Ladin also had previous roles as Counsel and Director of Business Development at Heart Corporation, where he engaged in venture capital and private equity investments, as well as mergers & acquisitions in early technology and internet companies, and started his career as a corporate transaction associate attorney at Clifford Chance, Rogers & Wells. In addition to legal, compliance, operations, and tax planning, Mr. Ladin manages a portfolio of venture capital, private equity, real estate and hedge fund investments, and regularly sits on boards to advise on capital financing, governance, mergers & acquisitions, and post-deal monitoring and dispute resolution. He currently serves as a board/committee member or observer for Decisive Point Group, LLC, K2 Integrity Holdings, Inc., Liquidnet Holdings, Inc., Madison Realty Capital Equity Fund I, LLC, Parvizi Surgical Innovations, LLC, and UniteUs, Inc. He received a J.D. from Georgetown University Law School in 1996 and a B.S. in Business Administration from University at Albany in 1993.

Dr. Nigel Lindner brings a unique blend of scientific, R&D, and commercial expertise to his role as Chief Innovation Officer at CLEU Diagnostics. Nigel has a proven track record of delivering breakthrough products in a variety of industries, most notably professional and consumer diagnostics, having served previously in numerous senior management positions over three decades, including Chief Innovation Officer at LumiraDx, CEO of Swiss Precision Diagnostics, Vice President of Global R&D at Alere Inc, and key strategic roles at Unilever R&D. Dr. Lindner is a renowned expert and distinguished leader in the field of point-of-care diagnostics, serving as key stakeholder to bring about transformative change in the industry. In addition to his role at CLEU Diagnostics, Nigel is also Chairman and Chief Scientific Officer of InVita Intelligence Ltd, a Healthcare Software company. Dr. Lindner received his PhD in Biotechnology from University of Cambridge. B.S. in 1986.

Scott Kellogg serves as Chief Business Officer of CLEU Diagnostics. Mr. Kellogg is an accomplished medical technology executive, with a three-decade career of building first-in-kind life science products for the pharma, biotech, digital health, and medical device industries. Scott has succeeded in building med-tech businesses in digital therapy, ultrasound surgical modalities, non-invasive transdermal diagnostics, neurostimulation, and therapeutic drug-device combinations. An inventor and engineer at heart, Scott has delivered results in fast-paced R&D and product development environments, and is also experienced at handling all matters related to regulatory strategy, clinical operations, GMP manufacturing, and intellectual property. Scott is currently CEO of GEM-Biosciences, a company he co-founded with MIT Professors Robert Langer and Giovanni Traverso. GEM-Biosciences promises to revolutionize treatment for diabetic ulcers with its breakthrough technology for delivery of therapeutic gases to wounds. Scott previously served as CEO at Suono Bio, a company focused on oral and topical delivery of biologics and nucleic acid medicines. Prior to that, Scott served as SVP in charge of medical devices at Akili Interactive Labs, Inc, leading development and FDA clearance / CE certification of a first-in-class therapeutic mobile application for the treatment of pediatric ADHD. Before joining Akili, Scott was a founding team member at Follica Bio, Afferent, Corp., Sontra Medical, Inc., and UltraCision, Inc., serving as VP of Business Operations, VP of Product Development, VP of R&D, and Director of Engineering. Additionally, he served in engineering leadership roles at both Mentor Medical, Inc. and Ethicon Endo-Surgery, Inc., now both part of J&J.

Dr. Javad Parvizi, MD, FRCS, is Co-Founder of CLEU Diagnostics and currently serves as a Director. Dr. Parvizi is a renowned surgeon and scientist with a career spanning over 25 years, most recently as Professor of Orthopedic Surgery at Acibadem University in Istanbul. Dr. Parvizi has earned worldwide recognition for his pioneering work in the management of periprosthetic joint infection and venous thromboembolism. Prior to joining Acibadem University, he served as the Director and Vice Chair of Research at the Rothman Institute. During his illustrious career, he has authored over 1,000 peer-reviewed scientific articles, penned 18 textbooks, and garnered over 100 awards from prestigious medical organizations worldwide. Dr. Parvizi has a stellar track record of securing research funding from prominent institutions, including the National Institutes of Health, Department of Defense, among others. After medical school, Dr. Parvizi completed training in cardiothoracic surgery in Great Britain. He then ventured to the United States in 1995, where he completed residency training in orthopedic surgery at Mayo Clinic. He also completed a prestigious fellowship on the management of hip disorders in young adults under the mentorship of Professor Reinhold Ganz at the Inselspital in Bern, Switzerland. In 2003, Dr. Parvizi joined the Rothman Orthopaedic Institute and held the position of James Edward Professor of Orthopedic Surgery at Sidney Kimmel School of Medicine until September 2023. Dr. Parvizi has served in leadership roles as president of the Musculoskeletal Infection Society (2013), Eastern Orthopedic Association (2018), and American Association of Hip and Knee Surgeons (AAHKS) ( 2023). Dr. Parvizi's dedication to education is exemplified by his training of over 2,000 research and clinical fellows and residents throughout his career. He continues to travel extensively, having visited more than 170 countries to deliver lectures and share his knowledge. His contributions have earned him honorary memberships in numerous global organizations. In 2017, Dr. Parvizi founded Parvizi Surgical Innovation (PSI) LLC, a highly successful incubator and accelerator for developing groundbreaking healthcare products that enhance patient care. CLEU Diagnostics was one of the first companies founded and incubated at Parvizi Surgical Innovation.

Dr. David Kirschman serves as a Director for CLEU Diagnostics. Dr. Kirschman is a former neurosurgeon and distinguished entrepreneur and operator with extensive experience in building medical device companies from product development to commercial sales & distribution. Dr. Kirschman previously founded X-spine Systems (now Xtant Medical), Orthophor (now part of BD), Aerobiotix, and, most recently, Orthomod. He holds over 80 issued US Patents for a wide range of medical devices. Dr. Kirschman received his BS in Biological Sciences from Colorado State University and M.D. from University of Colorado School of Medicine.

Ms. Fariba Kasemkhani is one of the founding members of CLEU Diagnostics and has been with the company since inception. She has served in various leadership positions, including most recently Vice President of Finance. Ms. Kasemkhani is an Electrical Engineer by training with nearly two decades of experience working for IBM leading numerous chip design projects. While working with the Watson team on the Blue Gene series of supercomputers, she was team lead for Compute Chip Blue Gene/L, FPU developer for Blue Gene/P, and technical lead for Link Chip Blue Gene/Q. She has a vast knowledge of verification and debugging of complex ASIC, microprocessors, and semi-custom chip designs. In addition, she was a Logic Designer in Gaming Processor (Xbox 360, Wii and PS3). She was awarded numerous distinctions while working for IBM.

Kam Ghofrani has served as Head of Engineering for LabSimple since 2021. Leveraging his interdisciplinary expertise honed during his Nanotechnology Engineering studies at the University of Waterloo, Kam seamlessly integrates advanced microfluidics, electronics, and control systems into diagnostic devices. With a robust background in research—including pioneering contributions in microfluidics and quantum science—he drives system cohesion from assay development to software-level controls. Prior to LabSimple, Kam co-founded ventures in lab-on-chip technology and biomedical diagnostics, cementing his reputation as a leader in engineering innovation. Passionate about fusing multiple disciplines, he consistently develops compact, efficient solutions that enhance precision and performance in lab automation.

Bayan Mashrequi has served as Lead Product Engineer for LabSimple since 2022. Bayan focuses on instrument design, system integration, and design for manufacturability. Bayan also has led development of advanced analytics and sensor technologies for the LabSimple core assembly. Bayan earned his Bachelor's degree in Industrial and Manufacturing Engineering from National University of Sciences and Technology and a Master's in Industrial Design from Rhode Island School of Design (RISD), graduating with the Thomas Edison award for his thesis. Passionate about fusing technology across multiple engineering disciplines, he specializes in developing products that optimize spatial efficiency, precision, and seamless integration. Bayan is a master when it comes to miniaturizing complex systems that require high density integration, and his skillset has clearly made its mark on the design of the LabSimple core module.

Kunj Patel has served as the Project Manager for LabSimple since 2022, focusing on program development from planning through execution. Kunj also heads quality assurance for in vitro diagnostic (IVD) products at CLEU Diagnostics. Kunj earned both her Bachelor's and Master's degrees in Mechanical Engineering from Embry-Riddle Aeronautical University, where she gained early experience in medical device development projects. She began her career as a Project Design Engineer at a med-tech startup specializing in patient-specific CMF/Orthopedic implants, developing expertise in quality management systems, product development, and business operations.

Jill is the principal at The JoLT Group, a consulting practice focused on the Life Science and Diagnostic field. She has spent the last 25 years cultivating a unique set of skills to assist companies in a variety of areas. She has a proven track record of leading teams through startups, turnarounds, product development/commercialization, and mergers and acquisitions and has been an asset to clients. Additionally, her extensive rolodex of strategics, investment bankers, industry analysts, and key opinion leaders makes her a strong connector of people and ideas. Known for exceptional interpersonal skills and tenacity, Jill has an extensive portfolio of closed licensing deals, joint ventures, and mergers and acquisitions. Jill has been an advisor for the National Science Foundation I-Corp competition, a judge for 43North Startup Competition, and a volunteer with the Make-A-Wish Foundation

Dr. Kisner, PhD, MBA is an accomplished strategic leader and company builder with over 30 years of experience in the laboratory diagnostics industry. A nationally recognized expert in instrument and reagent selection, as well as laboratory workflow design and automation, Dr. Kisner brings deep domain expertise to integrated health systems, academic medical centers, and large physician group practices across the United States. Dr. Kisner is the founder and President of NorthEast Clinical & Anatomic Pathology Solutions Inc (NECAPS), a consulting firm specializing in the technical and operational aspects of clinical and anatomic pathology. He has also previously served as Chief Operating Officer and Laboratory Director for Path Lab Inc, one of the fastest growing integrated health network laboratories, as well as Chief Laboratory Officer for Davita Laboratories. In addition to advising healthcare organizations, Dr. Kisner collaborates with in vitro diagnostic (IVD) companies on product design and go-to-market strategies. He has held advisory roles for prominent organizations such as Partners HealthCare, Cleveland Clinic, LumiraDx, and Akoya Biosciences and sits on multiple scientific advisory boards, is a trusted advisor to private equity firms investing in the diagnostics and laboratory sectors, and has invested in and serves on the Board of Directors of several ventures.